ES
PCRX icon

Equitec Specialists’s Pacira BioSciences PCRX Stock Holding History

Equitec Specialists’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,026
Closed -$49K – 110
2017
Q2 		$49K Sell
1,026
-4,620
-82% -$214K 0.01% 83
2017
Q1 		$257K Buy
+5,646
New +$244K 0.06% 48

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Equitec Specialists's PCRX Position: Q3 2017 in Review

Equitec Specialists sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 1,026 shares — an estimated $49K sold.

Equitec Specialists first reported a position in PCRX in Q1 2017 and held it in 2 quarters. The position peaked at $257K in Q1 2017. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • Equitec Specialists reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • Equitec Specialists sold 1,026 Pacira BioSciences shares in Q3 2017, an estimated $49K.
  • Equitec Specialists first reported a position in Pacira BioSciences in Q1 2017 and held it in 2 quarters.
  • Equitec Specialists's Pacira BioSciences position peaked at $257K in Q1 2017.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on Equitec Specialists's 13F filing for Q3 2017, filed 23 Oct 2017.